Replies to post #246326 on Biotech Values

[Whalatane]

rfj. I agree ..Oral trumps IV ( usually ) .....so heres the P2 data on KDNY's Altrassentan

https://investors.chinooktx.com/node/11971/pdf

58% reduction at 24 wks of treatment ....using tablets ...not IV .
Safety profile looks good vs Filspari .

So far I'm going with KDNY as best in class for IgaN Nephropathy
What do U think ?
Kiwi